Kyverna Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Kyverna Therapeutics's estimated annual revenue is currently $18.8M per year.
- Kyverna Therapeutics's estimated revenue per employee is $136,898
Employee Data
- Kyverna Therapeutics has 137 Employees.
- Kyverna Therapeutics grew their employee count by 29% last year.
Kyverna Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Product Officer | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Chief Business Officer | Reveal Email/Phone |
5 | Chief Human Resources Officer | Reveal Email/Phone |
6 | Chief Business Officer | Reveal Email/Phone |
7 | Chief Medical and Development Officer | Reveal Email/Phone |
8 | Head Human Resources | Reveal Email/Phone |
9 | Head Medical Affairs, Europe | Reveal Email/Phone |
10 | VP, Head GxP Quality | Reveal Email/Phone |
Kyverna Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Kyverna Therapeutics?
Kyverna is a cell therapy company engineering and developing a new class of curative living medicines for inflammatory and autoimmune diseases. Using its SmarTcellâ„¢ approach which includes synReg-T cell and synNotch CAR-T technology platforms, Kyverna reprograms T cells to target and selectively suppress or eliminate autoreactive immune cells. The company's goal is to develop therapies that are selective, potent and durable to tame autoimmunity. synNotch is a trademark of Gilead/Kite.
keywords:N/AN/A
Total Funding
137
Number of Employees
$18.8M
Revenue (est)
29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kyverna Therapeutics News
The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress or eliminate the...
Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for autoimmune diseases, has closed an oversubscribed $85m...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $20M | 138 | 1% | N/A |
#2 | $32.3M | 140 | 11% | N/A |
#3 | $53M | 147 | 7% | N/A |
#4 | $12.2M | 167 | 11% | $26.1M |
#5 | $27.9M | 169 | 21% | N/A |